ERBB2 and breast carcinoma: Based on the literature (Halpain and Dehmelt, 2006; Jijumon et al., 2022), we selected 16 proteins and compared their expression levels in more aggressive (MDA-MB-231 cell and TNBC in patients) and milder (MCF7 cell; ER+ and ER+HER2+ in patients) subtypes of breast cancer cell lines and patients using publicly available RNA-seq data (Messier et al., 2016; Chung et al., 2017).